Skye Bioscience Collaborates with Halozyme on Nimacimab Delivery

An update from Skye Bioscience ( (SKYE) ) is now available.

On December 18, 2025, Skye Bioscience, Inc. entered into a non-exclusive collaboration and license agreement with Halozyme, Inc. to use Halozyme’s ENHANZE drug delivery technology to develop a subcutaneous formulation of Skye’s antibody nimacimab, with Halozyme serving as the exclusive supplier of clinical and commercial rHuPH20 bulk drug product. The deal includes milestone payments tied to development, commercialization, and net sales thresholds, along with mid-single-digit royalties on global sales, reflecting a standard biotech licensing structure that could enhance Skye’s ability to deliver nimacimab more conveniently to patients and potentially strengthen its competitive position if the product advances successfully.

The most recent analyst rating on (SKYE) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Skye Bioscience stock, see the SKYE Stock Forecast page.

Spark’s Take on SKYE Stock

According to Spark, TipRanks’ AI Analyst, SKYE is a Underperform.

Skye Bioscience’s overall stock score is primarily hindered by significant financial challenges, including zero revenue and continuous losses. Despite strong earnings call highlights and a substantial cash position, the bearish technical analysis and valuation difficulties weigh heavily on the score.

To see Spark’s full report on SKYE stock, click here.

More about Skye Bioscience

Skye Bioscience, Inc. is a biopharmaceutical company focused on developing drug candidates, including the antibody nimacimab, and advancing them through clinical and commercial stages using innovative drug delivery technologies.

Average Trading Volume: 834,229

Technical Sentiment Signal: Sell

Current Market Cap: $29.81M

See more insights into SKYE stock on TipRanks’ Stock Analysis page.